×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KALA – kala bio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KALA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/4
06:30 am
kala
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgenc
High
Report
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgenc
1/5
04:10 pm
kala
KALA BIO Settles Approximately $10.6 million of Debt
Medium
Report
KALA BIO Settles Approximately $10.6 million of Debt
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/4
09:17 am
kala
Form 8-K KALA BIO, Inc. For: Mar 03
Low
Report
Form 8-K KALA BIO, Inc. For: Mar 03
2/20
04:06 pm
kala
Form 8-K KALA BIO, Inc. For: Feb 16
Low
Report
Form 8-K KALA BIO, Inc. For: Feb 16
2/17
04:21 pm
kala
Form SCHEDULE 13G/A KALA BIO, Inc. Filed by: BAKER BROS. ADVISORS LP
Medium
Report
Form SCHEDULE 13G/A KALA BIO, Inc. Filed by: BAKER BROS. ADVISORS LP
2/9
04:16 pm
kala
Form 3 KALA BIO, Inc. For: Jan 30 Filed by: Purdy Brendan P.
Medium
Report
Form 3 KALA BIO, Inc. For: Jan 30 Filed by: Purdy Brendan P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/3
Form 4 Kala Pharmaceuticals, For: Jan 02 Filed by: Brazzell Romulus K
26.4%
3/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock. 26.3%
8/8 Kala Pharmaceuticals Inc (NASDAQ: KALA) was given a new $9.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a "buy" rating on the stock. 24.0%
8/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $15.00. 17.2%
11/7 Form 10-Q Kala Pharmaceuticals, For: Sep 30 10.8%
4/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 8.0%
4/1 Form 4 Kala Pharmaceuticals, For: Mar 30 Filed by: Chen Hongming 7.7%
10/21 Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 6.8%
4/13 Form 4 Kala Pharmaceuticals, For: Apr 09 Filed by: Brazzell Romulus K 6.8%
6/3 Form 4 Kala Pharmaceuticals, For: May 30 Filed by: Rosen Howard B 6.2%
3/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock. 26.3%
8/8 Kala Pharmaceuticals Inc (NASDAQ: KALA) was given a new $9.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a "buy" rating on the stock. 24.0%
8/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $15.00. 17.2%
11/7 Form 10-Q Kala Pharmaceuticals, For: Sep 30 10.8%
4/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 8.0%
4/1 Form 4 Kala Pharmaceuticals, For: Mar 30 Filed by: Chen Hongming 7.7%
10/21 Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 6.8%
4/13 Form 4 Kala Pharmaceuticals, For: Apr 09 Filed by: Brazzell Romulus K 6.8%
6/3 Form 4 Kala Pharmaceuticals, For: May 30 Filed by: Rosen Howard B 6.2%
TOP News Decliners
3/11
Form 8-K Kala Pharmaceuticals, For: Mar 10
-16.0%
8/6 Form 8-K Kala Pharmaceuticals, For: Aug 06 -15.9%
8/3 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.75 price target on the stock. -15.1%
12/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was downgraded by analysts at Bank of America Corp from a "buy" rating to a "neutral" rating. They now have a $6.00 price target on the stock, down previously from $9.00. -13.2%
3/12 Form 424B5 Kala Pharmaceuticals, -8.8%
4/30 Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call -8.7%
1/21 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. -8.4%
4/28 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -7.5%
3/10 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its price target raised by analysts at Wedbush from $51.00 to $52.00. They now have an "outperform" rating on the stock. -7.1%
5/9 Form 10-Q Kala Pharmaceuticals, For: Mar 31 -6.5%
8/6 Form 8-K Kala Pharmaceuticals, For: Aug 06 -15.9%
8/3 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.75 price target on the stock. -15.1%
12/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was downgraded by analysts at Bank of America Corp from a "buy" rating to a "neutral" rating. They now have a $6.00 price target on the stock, down previously from $9.00. -13.2%
3/12 Form 424B5 Kala Pharmaceuticals, -8.8%
4/30 Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call -8.7%
1/21 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. -8.4%
4/28 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -7.5%
3/10 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its price target raised by analysts at Wedbush from $51.00 to $52.00. They now have an "outperform" rating on the stock. -7.1%
5/9 Form 10-Q Kala Pharmaceuticals, For: Mar 31 -6.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: